[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK277488A - Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen - Google Patents

Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen

Info

Publication number
DK277488A
DK277488A DK277488A DK277488A DK277488A DK 277488 A DK277488 A DK 277488A DK 277488 A DK277488 A DK 277488A DK 277488 A DK277488 A DK 277488A DK 277488 A DK277488 A DK 277488A
Authority
DK
Denmark
Prior art keywords
hmg
phosphorus
preparation
manufacturing
coa reductase
Prior art date
Application number
DK277488A
Other languages
English (en)
Other versions
DK277488D0 (da
Inventor
Donald Steven Karanewsky
Scott Adams Biller
Eric Michael Gordon
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of DK277488D0 publication Critical patent/DK277488D0/da
Publication of DK277488A publication Critical patent/DK277488A/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32Esters thereof
    • C07F9/3205Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211Esters of acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/36Amides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • C07F9/4403Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407Amides of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK277488A 1987-05-22 1988-05-20 Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen DK277488A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5328187A 1987-05-22 1987-05-22
US10968087A 1987-10-19 1987-10-19

Publications (2)

Publication Number Publication Date
DK277488D0 DK277488D0 (da) 1988-05-20
DK277488A true DK277488A (da) 1988-11-23

Family

ID=26731667

Family Applications (1)

Application Number Title Priority Date Filing Date
DK277488A DK277488A (da) 1987-05-22 1988-05-20 Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen

Country Status (24)

Country Link
JP (1) JP2680347B2 (da)
KR (1) KR880013958A (da)
CN (1) CN88103091A (da)
AU (1) AU610591B2 (da)
BE (1) BE1004193A3 (da)
CH (1) CH676984A5 (da)
DE (1) DE3817375C2 (da)
DK (1) DK277488A (da)
ES (1) ES2009918A6 (da)
FI (1) FI89493C (da)
FR (1) FR2615508B1 (da)
GB (1) GB2205837B (da)
GR (1) GR1000959B (da)
HU (1) HU205125B (da)
IE (2) IE63760B1 (da)
IL (1) IL86464A (da)
IT (1) IT1217685B (da)
NL (1) NL8801330A (da)
NO (1) NO882218L (da)
NZ (1) NZ224733A (da)
PH (1) PH25350A (da)
PL (1) PL154877B1 (da)
PT (1) PT87539B (da)
SE (1) SE503210C2 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224734A (en) * 1987-05-22 1991-04-26 Squibb & Sons Inc Organophosphorus hmg-coa reductase inhibitors, and pharmaceutical compositions
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
CA2042526A1 (en) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5202327A (en) * 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
GB9126144D0 (en) * 1991-12-10 1992-02-12 British Bio Technology Compounds
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
BR9913831A (pt) 1998-09-17 2001-05-29 Bristol Myers Squibb Co Processo para tratamento de arteriosclerose empregando um inibidor de ap2 e combinação
HUP0600232A2 (en) 2001-04-11 2006-08-28 Bristol Myers Squibb Co Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
YU31004A (sh) 2001-10-18 2006-08-17 Bristol-Myers Squibb Company Mimetici humanog glukagonu sličnog peptida-1 i njihova upotreba u lečenju dijabetesa i srodnih stanja
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
ES2344057T3 (es) 2002-10-23 2010-08-17 Bristol-Myers Squibb Company Inhibidores de la dipeptidil peptidasa iv basados en nitrilos de glicina.
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
CA2558766A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
WO2007053819A2 (en) 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
IN2009KN04568A (da) 2007-06-01 2015-08-28 Univ Princeton
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CN101808995A (zh) 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP2411005A1 (en) 2009-03-27 2012-02-01 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
EA201200570A1 (ru) 2009-10-09 2012-11-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
RU2558798C2 (ru) 2009-11-13 2015-08-10 Астразенека Аб Составы таблетки с немедленным высвобождением
AU2010319438B2 (en) 2009-11-13 2015-05-21 Astrazeneca Uk Limited Reduced mass metformin formulations
CA2780939C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Bilayer tablet formulations
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
ES2575860T3 (es) 2010-07-09 2016-07-01 Bhv Pharma, Inc. Sistema de administración de liberación inmediata/retardada de combinación para productos farmacéuticos de semivida corta que incluyen remogliflozina
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
BR112015011298B1 (pt) 2012-11-20 2021-12-14 Lexicon Pharmaceuticals, Inc Inibidores de cotransportador 1 de glicose de sódio e composição farmacêutica que os compreende
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN104610262B (zh) * 2013-11-01 2017-06-06 上海医药工业研究院 联苯类化合物、中间体、制备方法、药物组合物及其应用
SG11201708323SA (en) 2015-04-30 2017-11-29 Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
CA3105626A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
BR112021004839A2 (pt) 2018-09-26 2021-06-08 Lexicon Pharmaceuticals, Inc. formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA828650B (en) * 1981-12-01 1983-09-28 Hunt Chem Corp Philip A Herbicidal compositions and method using phosphonalkanoic acids, esters and salts thereof
FR2596393B1 (fr) * 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
NZ224734A (en) * 1987-05-22 1991-04-26 Squibb & Sons Inc Organophosphorus hmg-coa reductase inhibitors, and pharmaceutical compositions

Also Published As

Publication number Publication date
JP2680347B2 (ja) 1997-11-19
PL272597A1 (en) 1989-03-06
FI882384A0 (fi) 1988-05-20
IE930324L (en) 1988-11-22
IL86464A0 (en) 1988-11-15
BE1004193A3 (fr) 1992-10-13
IL86464A (en) 1993-06-10
AU1650888A (en) 1988-11-24
IT8820682A0 (it) 1988-05-20
IE63760B1 (en) 1995-06-14
HU205125B (en) 1992-03-30
NO882218L (no) 1988-11-23
PT87539A (pt) 1989-05-31
FI89493C (fi) 1993-10-11
JPS6456689A (en) 1989-03-03
SE503210C2 (sv) 1996-04-22
PT87539B (pt) 1992-09-30
PH25350A (en) 1991-05-13
GR880100331A (en) 1989-02-23
SE8801903L (sv) 1988-11-23
NZ224733A (en) 1990-12-21
DK277488D0 (da) 1988-05-20
ES2009918A6 (es) 1989-10-16
FI89493B (fi) 1993-06-30
FI882384A7 (fi) 1988-11-23
FR2615508B1 (fr) 1994-11-25
GR1000959B (el) 1993-03-16
HUT49358A (en) 1989-09-28
CN88103091A (zh) 1988-12-21
NO882218D0 (no) 1988-05-20
GB2205837A (en) 1988-12-21
IE881543L (en) 1988-11-22
AU610591B2 (en) 1991-05-23
GB8811929D0 (en) 1988-06-22
DE3817375C2 (de) 1997-04-30
PL154877B1 (en) 1991-09-30
KR880013958A (ko) 1988-12-22
CH676984A5 (da) 1991-03-28
DE3817375A1 (de) 1988-12-08
FR2615508A1 (fr) 1988-11-25
NL8801330A (nl) 1988-12-16
GB2205837B (en) 1991-11-20
SE8801903D0 (sv) 1988-05-20
IT1217685B (it) 1990-03-30

Similar Documents

Publication Publication Date Title
DK277488A (da) Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen
NO177212C (no) Fremgangsmåte ved fremstilling av deig og bröd, samt enzympreparat for anvendelse ved fremgangsmåten
NO902272D0 (no) Metall-karbidgjenstander og fremgangsmaate ved deres fremstilling.
DK328585D0 (da) Modificerede succinimider, fremgangsmaade til deres fremstilling samt deres anvendelse
DE3681991D1 (de) Hmg-coa-reduktase-hemmungskoerper.
FI921790A7 (fi) Säiliö ja menetelmä sen valmistamiseksi
NO884309D0 (no) Lagringsstabile yogurtprodukter og fremgangsmaate for deres fremstilling.
DK198387D0 (da) 1-hydroxy-2-pyridoner, deres fremstilling og anvendelse samt ved fremgangsmaaden anvendelige mellemprodukter og disses fremstilling
DK148590A (da) Homogene, isaer flerfarvede strukturerede kunststofbaner eller -plader samt fremgangsmaade til deres fremstilling
DK698088A (da) Piperidinylforbindelser, deres anvendelse samt mellemprodukter til brug ved fremstillingen af disse
DK277388A (da) Phosphorholdige hmg-coa-reduktase-inhibitorer, mellemprodukter og fremgangsmaade
FI893004A7 (fi) 5-oksygenoituja HMG-CoA-reduktaasi-inhibiittoreita
DK361288A (da) Hydroxyethylazolylderivater, deres fremstilling og anvendelse samt mellemprodukter til fremstilling og disses fremstilling
IT8820130A0 (it) Smalto o vernice per unghie avente caratteristiche fotocromatiche erelativo procedimento di preparazione.
DK326085A (da) 4-amino-2-phenylquinoliner, deres fremstilling og anvendelse samt ved fremstillingen anvendelige mellemprodukter
NO903801D0 (no) Alkalipullunase, mikroorganisme og fremgangsmaate ved fremstilling derav.
DK332287A (da) Antibiotika ll-e19020-alfa og ll-e19020-beta, deres fremstilling og anvendelse samt mikroorganisme til fremstillingen
DK39486D0 (da) 4,4-diakyl-2-azetidinoner, fremstilling og anvendelse deraf, samt vedfremstillingen anvendelige mellemprodukter og deres fremstilling
DK610388A (da) (6-(hetero) aryloxy-naphthalin-2-yl-oxy)-alkancarboxylsyrederivater, deres fremstilling og anvendelse samt ved fremgangsmaaden anvendelige mellemprodukter og disses fremstilling
DK192989D0 (da) 3,4-dihydroxypyrrolidin-2-on-derivater, deres fremstilling og anvendelse samt ved fremgangsmaaden anvendelige mellemprodukter
NO880628L (no) Annelerte azepinon- og azocinon-derivater, fremgangsmaate til deres fremstilling, midler som inneholder dem og deresanvendelse, samt mellomprodukter ved deres fremstilling.
DK490985D0 (da) Benzoylurinstoffer, deres fremstilling og anvendelse, samt ved fremstillingen anvendelige mellemprodukter og fremstilling deraf
EP0306263A3 (en) Novel hmg-coa reductase inhibitors
NO901934D0 (no) Fraktureringsmateriale, samt anvendelse av det ved produksjon av hydrokarboner.
DK548487A (da) Substituerede aminoketaler, deres fremstilling og anvendelse samt ved fremgangsmaaden anvendelige dioxalaner og disses fremstilling

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment